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During the last 15 years, accumulating experimental and
clinical evidence suggested that the epileptic brain may
undergo significant modifications as a result of recurrent
seizures or due to the underlying seizure etiology. This
concept of epilepsy as an evolving neurodegenerative
process is best exemplified by temporal lobe epilepsy.
According to current thinking, in patients with temporal
lobe epilepsy a triggering factor, such as complicated
febrile seizures or head trauma, sets in motion the process
of epileptogenesis, that is a cascade of events leading to a
gradual increase of brain excitability and eventually the
occurrence of spontaneous seizures. In a subset of
patients, this process further evolves due to a complex
interaction of neurodegenerative and neuroplastic
changes brought about by recurrent seizures. At a clinical
level, this evolving process becomes evident by the onset
of pharmacoresistant epileptic seizures sometimes accom-
panied by cognitive decline. The current pharmacological
treatment of epilepsy is directed towards suppressing epi-
leptic seizures and therefore it is essentially a symptomatic
approach. The recent unraveling of the cellular mecha-
nisms underlying epileptogenesis, however, has led to the
discovery of pharmacological agents with neuroprotective
and antiepileptogenic properties, which include a number
of clinically available antiepileptic drugs. These agents
hold promise as disease modification strategies which
may ultimately improve the long-term outcome of epilep-
tic patients by mitigating cognitive compromise and pre-
venting the transition to pharmacoresistance. This
presentation reviews the available evidence regarding the
neuroprotective properties of antiepileptic drugs and dis-
cusses some methodological difficulties in designing clin-
ical trials with a view to investigating neuroprotective
strategies in epilepsy.
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